脑脊液C4A水平增加首发精神病患者患精神分裂症。研究设计的概述。b在发现队列(KaSP),首发精神病患者(聚全氟乙丙烯)开发了精神分裂症(FEP-SCZ;n = 29)显示明显高于脑脊液(CSF) C4A浓度比健康对照组(高碳钢;患者n = 20)或聚全氟乙丙烯不开发SCZ (FEP-nSCZ;n = 15)(高碳钢:0.28 fmol / ul;95%可信区间[CI] = 0.24 - -0.33, FEP-nSCZ: 0.29 fmol / ul;CI = 0.22 - -0.35, FEP-SCZ: 0.41;CI = 0.34 - -0.45,调整P [FEP-SCZ与高碳钢]= 0.025,调整P [FEP-SCZ vs FEP-nSCZ] = 0.037)。c CSF C4B浓度被类似的跨组(高碳钢(n = 20): 0.43 fmol / ul; CI = 0.36–0.57, FEP-nSCZ [n = 15]: 0.38 fmol/ul; CI = 0.30–0.49, FEP-SCZ [n = 28]: 0.46 fmol/ul; CI = 0.44–0.58, adjusted P [FEP-SCZ vs. HCs]=0.550, adjusted P [FEP-SCZ vs. FEP-nSCZ]=0.098). d In the replication cohort (GRIP), patients with FEP-SCZ (n = 17) displayed significantly higher CSF C4A concentrations as compared to HCs (n = 21) or patients with FEP-nSCZ (n = 13) (HC: 0.34 fmol/ul; CI: 0.31–0.47, FEP-nSCZ: 0.28 fmol/ul; CI: 0.25–0.33, FEP-SCZ: 0.50 fmol/ul; CI: 0.41-0.56, adjusted P [FEP-SCZ vs. HCs]= 0.047, adjusted P [FEP-SCZ vs. FEP-nSCZ]=0.001), while (e) CSF C4B concentration were similar across groups (HCs [n = 21]: 0.51 fmol/ul; CI = 0.44–0.63, FEP-nSCZ [n = 14]: 0.56 fmol/ul; CI = 0.47–0.72, FEP-SCZ [n = 17]: 0.55 fmol/ul; CI = 0.41–0.65, adjusted P [FEP-SCZ vs. HCs]=0.999, adjusted P [FEP-SCZ vs. FEP-nSCZ]=0.708). Bar graphs represent medians and error bars represent 95% CIs. Data were analyzed using Kruskal–Wallis H tests followed by post-hoc tests. Significance was set to P < 0.05. All reported p-values are two-sided. Figure 1a was created with BioRender.com. Source data for graphs in Fig. 1b–e are provided in the Source Data file. Credit:自然通讯(2022)。DOI: 10.1038 / s41467 - 022 - 33797 - 6
